HAIFA, Israel--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NasdaqCM:PSTI)(DAX:PJT), will receive a total of $2.3 million in funding for its stem cell programs from the Office of the Chief Scientist (OCS) at the Ministry of Industry, Trade and Labor of Israel. This is an increase from the previously announced amount of $1.9 million. Funds will be utilized primarily to support the Company’s clinical trials of PLX-PAD, which is the first placenta derived stem cell product cultured in Pluristem’s proprietary PluriXTM 3D bioreactor system. PLX-PAD is targeted for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
